ArriVent BioPharmaAVBP
About: ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.
Employees: 52
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
175% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 12
140% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 10
24% more capital invested
Capital invested by funds: $613M [Q3] → $757M (+$145M) [Q4]
20% more funds holding in top 10
Funds holding in top 10: 5 [Q3] → 6 (+1) [Q4]
19% more funds holding
Funds holding: 67 [Q3] → 80 (+13) [Q4]
7.3% more ownership
Funds ownership: 77.17% [Q3] → 84.47% (+7.3%) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
B. Riley Securities Kalpit Patel 9% 1-year accuracy 1 / 11 met price target | 106%upside $37 | Buy Initiated | 20 Mar 2025 |
Guggenheim Michael Schmidt 25% 1-year accuracy 9 / 36 met price target | 150%upside $45 | Buy Initiated | 10 Mar 2025 |
HC Wainwright & Co. Robert Burns 15% 1-year accuracy 26 / 171 met price target | 117%upside $39 | Buy Reiterated | 7 Mar 2025 |
Financial journalist opinion









